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ABSTRACT
Objective: Adiponectin is a unique anti-atherogenic adipocytokine. Regulation of adiponectin secretion is dysfunctional in cardiovascular dis-
eases. The current trial study assessed the effects of omega-3 fatty acids with or without vitamin E on adiponectin gene expression in periph-
eral blood mononuclear cells and serum adiponectin and adipocyte fatty acid-binding protein (A-FABP; also called ap2 and FABP4) levels in 
patients with coronary artery disease (CAD).
Methods: This randomized, double-blind, placebo-controlled trial included 67 male patients with CAD. First of the four group of participants received 
4 g/day omega-3 fatty acids plus 400 IU/day vitamin E (OE), second group 4 g/day omega-3 fatty acids plus vitamin E placebo (OP), or both omega-3 
fatty acid and vitamin E placebos (PP) for 8 weeks. Adiponectin gene expression and serum adiponectin and FABP4 levels were evaluated.
Results: The combination of omega-3 fatty acids and vitamin E in patients with CAD affected their serum adiponectin and FABP4 levels and the 
adiponectin/FABP4 ratio significantly. In the OP group, serum adiponectin levels did not change significantly. Consumption of omega-3 fatty 
acids with and without vitamin E had no significant effect on adiponectin gene expression.
Conclusion: Omega-3 fatty acids with or without vitamin E improve adiponectin levels in patients, without any significant changes in adiponec-
tin gene expression. This nutritional intervention may prevent complications in patients with CAD because of increased adiponectin levels.
(Anatol J Cardiol 2015; 15: 981-9)
Key words: coronary artery disease, omega-3 fatty acids, vitamin E, adiponectin, adipocyte fatty acid-binding protein
981
Atena Ramezani 1,*, Fariba Koohdani 1, Abolghasem Djazayeri 2, Ebrahim Nematipour 3, 
Seyed Ali Keshavarz 4, Ali-Akbar Saboor-Yaraghi 1, Mohammad-Reza Eshraghian 5, Abbas Yousefinejad 1, 
Hassan Javanbakht 1, Mahnaz Zarei 1, Sanaz Gholamhosseini 1, Mahmoud Djalali 1
*Department of Basic sciences and Nutrition, Faculty of Health, Mazandaran University of Medical Sciences; Sari-Iran 
Departments of 1Molecular and Cellular Nutrition, 2Community Nutrition, 3Cardiology, 4Clinical Nutrition, 5Biostatistics, 
School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences; Tehran-Iran
Effects of administration of omega-3 fatty acids with or without 
vitamin E supplementation on adiponectin gene expression in PBMCs 
and serum adiponectin and adipocyte fatty acid-binding protein levels 
in male patients with CAD
Introduction
Cardiovascular diseases (CVDs) are the leading cause of 
mortality and the fifth leading cause of disability and morbidity in 
the world. According to the World Health Organization (WHO), 
an estimated 17.3 million people died from CVDs in 2008, repre-
senting 30% of all global deaths (1). During the 20th century, the 
percentage of all deaths due to CVDs has increased from 10% to 
30% and it is estimated that almost 23.6 million people will die 
from CVDs by 2030 if the current rates remain unchanged (2). In 
Iran, nearly 15 million people have been suffering from CVDs and 
nearly 317 of the daily 750 deaths occur on account of CVD (3). 
In fact, CVDs are one of the most life-threatening diseases and 
are the underlying cause in approximately 70% of all deaths in 
people over 75 years and 25% of deaths in people over 30 years (4). 
CVDs account for nearly half of the deaths due to non-communica-
ble diseases in Iran (4, 5). Studies have revealed that dietary factors 
play a major role in the prevention and management of CVDs (2, 
6-10). Consumption of omega-3 fatty acids from plant and marine 
resources appears to be useful because they improve endothelial 
function and reduce inflammatory responses, thrombosis risk, 
arrhythmias, and atherosclerotic plaque growth (8, 11-13).
Adiponectin is an adipocytokine secreted by adipose tissues 
(adipocytes); it has 244 amino acids and was first discovered in 
1995. Adiponectin is a unique anti-atherogenic and anti-inflam-
matory adipocytokine. Studies have shown that secretion of 
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adiponectin and expression of its receptor are reduced in patients 
with CVDs (11, 14-16). The gene responsible for adiponectin is 
located on chromosome 3q27. Adiponectin circulates in blood 
plasma in the form of low-molecular-weight (LMW) trimers, medi-
um-molecular-weight (MMW) hexamers, and high-molecular-
weight (HMW) multimers (14, 16-20). Epidemiological studies have 
shown that decreased adiponectin levels are associated with 
increased risk of CVDs (19), hypertension, and blood lipid abnor-
malities (21). In vitro studies have shown that adiponectin prevents 
the progression of atherosclerosis by inhibiting the production of 
pro-inflammatory agents through the inhibition of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) and phos-
pho-Akt and plays a central role in the regulation of macrophages 
switching from the M1 to M2 phenotype with an increase of anti-
inflammatory agents (17). Laboratory studies have demonstrated 
that lower adiponectin levels can result in an increase in the inflam-
matory processes in CVDs (17, 22). Vitamin E is a fat-soluble vitamin 
with antioxidant properties. Of the 8 natural vitamers of vitamin E, 
α-tocopherol and γ-tocopherol are the most common forms in the 
plasma (21). In addition to its antioxidant properties, vitamin E plays 
a critical role in the regulation of gene expression involved in cell 
cycle, inflammation, cell adhesion, cell signaling, lipid uptake, and 
gene expression of adiponectin (21).
Adipocyte fatty acid-binding protein (A-FABP), also called 
ap2 and FABP4, belongs to the large family of intracellular lipid-
binding proteins with an average molecular weight. It is pro-
duced by adipose tissues and then released into the blood cir-
culation (22, 23). Studies have indicated that this compound is 
possibly associated with insulin resistance, hyperglycemia, lipid 
abnormalities, and increased pro-inflammatory factors (23). In 
fact, A-FABP is able to bond with hydrophobic compounds such 
as saturated fatty acids (SFAs), which results in the accumula-
tion of cholesterol esters, inducing abnormalities of lipid metab-
olism and inflammation (23). Adiponectin and A-FABP are 
involved in the pathogenesis of atherosclerosis in different man-
ners; adiponectin, as a compound with anti-inflammatory prop-
erties, and A-FABP, as a pro-inflammatory factor, can contribute 
to the incidence and progression of CVDs (22). The A-FABP/
adiponectin ratio has been shown to be a more useful marker in 
CVDs than either of these parameters alone (22). Therefore, the 
current trial study was conducted to investigate the effects of 
administration of omega-3 fatty acids with or without vitamin E 
supplementation on adiponectin gene expression in peripheral 
blood mononuclear cells (PBMCs) and serum adiponectin and 
A-FABP levels in patients with coronary artery disease (CAD).
Methods
Study design and participants
This study was a randomized, double-blind, placebo-controlled 
trial that included 67 male patients suffering from CVDs with more 
than 50% stenosis proven by at least 1 coronary angiogram in the last 
3 months. Non-smoking patients with a body mass index (BMI) of ≤30 
and no infections, allergies, thyroid deficiencies, diabetes, or kidney 
and liver diseases were selected. The participants were recruited 
between July 2012 and June 2013 from the Tehran University of 
Medical Sciences Educating Hospital. The participants first signed 
an approval and were then familiarized with the study scope and 
methodology. Using a randomized permuted block method, the 
patients were assigned to receive 8 weeks of 4 g/day of omega-3 fatty 
acids and vitamin E resembling placebo (OP), 4 g/day of omega-3 fatty 
acids and vitamin E (OE), or omega-3 fatty acid and vitamin E placebo 
softgels (PP) with their lunch and dinner. Blood samples were col-
lected at baseline and at the end of week 8. Nutritionist IV and Version 
18.0; SPSS Inc., Chicago, USA, software were used for the analysis of 
dietary data and statistical analyses, respectively.
The study was approved by the Ethical Committee of Tehran 
University of Medical Sciences (reference no.: 86686). The study 
was registered in the Iranian Registry of Clinical Trials (IRCT) 
(IRCT2013080514273N1).
Information questionnaires
A general information questionnaire including questions such 
as age and disease period was provided to the participants. 
Twenty-four-hour food recalls were collected at the beginning and 
end of the study on 2 nonconsecutive days. Physical activities were 
assessed using the International Physical Activity Questionnaire 
(IPAQ). The physical activity questionnaire evaluates physical activ-
ity levels in terms of metabolic equivalent of task (MET). In this 
study, physical activity was categorized in to 3 different levels 
according to METs: low: <600 MET-min/week; moderate: 600-3000 
MET-min/week; and severe: >3000 MET-min/week).
Anthropometric measurements
Height, weight, and waist and hip circumferences were mea-
sured before and after the study. All anthropometric measurements 
were performed according to the methods approved by the WHO. 
Weight was measured to the nearest 0.01 kg using a digital scale 
(Seca, Clara 803, Germany) with the patient minimally clothed and 
barefoot. Height was measured to the nearest 0.1 cm using a stadi-
ometer (Seca, Germany) with the patient barefoot. Waist and hip 
circumferences were measured using a non-stretch tape (Seca, 201, 
Germany) and the mean of 2 measurements was recorded. BMI was 
calculated by dividing the patient’s weight in kilogram by the squared 
height in meter. The waist-to-hip ratio (WHR) was calculated by divid-
ing the waist circumference by the hip circumference.
Omega-3 fatty acid supplementation and placebos
Omega-3 fatty acid softgels containing 180 mg of eicosapen-
taenoic acid (EPA) and 120 mg of docosahexaenoic acid (DHA) 
and placebo softgels containing paraffin were provided by 
Minoo Pharmaceutical, Cosmetic and Hygienic Co., Iran. 
Placebos were phenotypically similar to the supplements.
Blood sampling
Venous blood (10 mL) was collected from the patients’ ante-
cubital vein under sterile conditions after 12-14 h of fasting 
before and after the study. The blood sample (8 mL) was trans-
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ferred to a sterile heparinized tube. Serum was separated from 
the whole blood sample and stored at -80°C until use. Adiponectin 
levels were assessed using an enzyme-linked immunosorbent 
assay (ELISA) kit (Mediagnost, Germany). Serum A-FABP levels 
were determined using a commercially available ELISA kit 
(Bioassay Technology Laboratory, China).
Isolation of PBMCs for assessment of adiponectin gene 
expression
First, 8 mL of phosphate-buffered saline (PBS) were added to 8 mL of 
heparinized blood in a 45-mL sterile tube and vortexed. Then, the mixture 
was slowly poured in a tube containing 8 mL of Ficoll®, followed by cen-
trifugation at 2500 rpm for 2 min. The buffy coat layer was transferred to 
another sterile tube. Then, the same volume of PBMCs was taken and 
PBS was added to wash. It was centrifuged at 1600 rpm for 15 min. To 
dissolve the cell sediment, 150 mL of PBS was added to the cells and 
pipetted several times and then transferred to an RNase-free microtube.
Isolation of RNA and cDNA synthesis
RNA was extracted using the RNeasy® Plus Mini kit (Qiagen, 
Germany) according to the manufacturer’s instructions. cDNA 
was extracted from RNA by the QuantiTect® reverse transcrip-
tase kit (Qiagen, Germany) and stored at -20°C until use. To 
assess the intensity of gene expression, the StepOne® real-time 
PCR system (Applied Biosystems, USA) was used. PCR was 
performed in a final volume of 20 μL, including 0.5 μL of each 
primer, 7 μL of SYBR Green® Power PCR Master Mix (2×) 
(Applied Biosystems, USA), and sufficient amount of sterile dis-
tilled water. To calculate the gene expression, the following 
formula for 2-ΔΔct was used: 2-[(CT of the target gene after trial-CT of β-actin after trial)]-
[(CT of the target gene before trial-CT of β-actin before trial)].
Primer design method
Target genes and their mRNA transcript sequences were 
obtained from the Ensembl website. Primers were modified 
according to the optimal PCR conditions. Primers for the house-
keeping gene β-actin were selected and modified on the basis of 
previous studies. The primer sequences used in the current study 
were as follows: adiponectin: AGGCCGTGATGGCAGGAGATG 
(forward) and CTGAATGCTGAGCGGTATACATAAG (reverse) and 
β-actin: CCTGGCACCCAGCACAATGAAG (forward) and 
CTAAGTCATAGTCCGCCTAGAAG (reverse).
Statistical analysis
SPSS, version 18.0 (SPSS Inc., Chicago, USA) software was used 
for statistical analyses. Data were presented as mean±standard error 
(SE). Kolmogorov-Smirnov test was used to check the normality of data 
distribution. A paired t-test was used to compare the means of the 
variables before and after the study in each group. One-way analysis of 
variance (ANOVA) was used to compare the mean of the variables 
between the groups. The chi-square test was used to compare ordinal 
and categorical data between the groups. The reported p values were 
2-sided and p values of <0.05 were considered significant.
Results
Sixty-seven male patients with CAD were equally divided into 
the OP, OE, and PP groups. During the study, 3 patients were hospi-
talized for heart surgery and 2 patients withdrew on account of 
personal reasons. Therefore, 62 patients completed the study, 
including 22, 20, and 20 patients in the OP, OE, and PP groups, 
respectively. The mean±SD age was 54.68±1.27 years, 56.30±1.62 
years, and 58.50±1.33 years in the OP, OE, and PP groups, respec-
tively. No significant differences were seen between the groups in 
terms of age (p=0.16). The duration of the disease in the OP, OE, and 
PP groups was 3.28±0.93 years, 2.66±0.88 years, and 5.29±1.39 years, 
respectively, with no statistically significant difference between the 
groups (p=0.22). The baseline characteristics of the patients, such 
as serum lipid profiles and blood pressure, are shown in Table 1.
Anthropometric variables
The anthropometric variables, including height, weight, BMI, 
waist and hip circumferences, and WHR, are shown in Table 2. 
No significant differences were seen in the anthropometric find-
ings between the experimental groups. The differences were 
not significant between the values at the beginning and end of 
the study for any of the anthropometric variables.
Nutrient intake
The means±SE of intake are described in Table 3. No signifi-
cant differences were observed in energy, macronutrient, and 
other nutrient intake between the groups at the beginning and 
end of the study. Comparison of the mean differences in energy 
and macronutrients between the beginning and end of the study 
showed no significant changes between the 3 groups.
 OP (n=22) OE (n=20) PP (n=20) P#
Triglyceride, mg/dL 159.95±12.31 176.50±17.99 189.22±19.54 0.45
Total cholesterol, mg/dL 166.16±7.21 185.15±9.12 161.88±7.38 0.10
LDL cholesterol, mg/dL 101.82±4.61 109.10±4.59 102.35±5.17 0.49
HDL cholesterol, mg/dL 32.85±1.57 31.05±1.57 32.42±1.61 0.78
Systolic blood pressure, mm Hg 124.23±3.85 124.45±3.70 128.80±2.72 0.58
Diastolic blood pressure, mm Hg 80.59±2.63 81.60±2.51 78.85±2.19 0.73
HDL - high-density lipoprotein; LDL - low-density lipoprotein; OE - omega-3 fatty acid & vitamin E; OP - omega-3 fatty acid & placebo; PP - placebo & placebo.*Mean±SE; #ANOVA
Table 1. Baseline characteristics of the patients*
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Fatty acid intake
The dietary intake of omega-3 fatty acids, omega-6 fatty 
acids, and SFAs is described in Table 4. The distribution of 
omega-3 and omega-6 fatty acids shifted to normal after loga-
rithmic transformation. No statistical differences or significant 
changes were seen in the intake of omega-3 fatty acids, omega-
6 fatty acids, and SFAs between the experimental groups.
Serum adiponectin and FABP4 levels
The mean±SE serum adiponectin and FABP4 levels at baseline 
and week 8 are shown in Table 5. At the end of the study, serum 
adiponectin levels were significantly different between the OP and 
PP groups (p=0.02) and between the OE and PP groups (p<0.001). 
However, serum adiponectin levels were not significantly different 
between the OP and OE groups (p=0.21). At the beginning and end 
of the study, no significant differences in serum FABP4 levels were 
seen between the 3 groups. However, FABP4 levels in the OP group 
were significantly decreased at the end of the study compared with 
the baseline (p=0.04) and OE group (p=0.02). The difference was not 
significant between the OP and OE groups.
Adiponectin gene expression
Adiponectin gene expression changes are shown in Table 6. After 
2 months of study, no significant changes were seen in adiponectin 
gene expression in any of the 3 groups. Comparison of the mean dif-
ference in adiponectin gene expression between the beginning and 
end of the study showed no significant changes in the 3 groups.
Physical activity
No significant differences were reported in physical activity 
of the participants in all groups before and after the study 
(Table 7). Data showed that the participants’ physical activity did 
not change significantly.
Discussion
The current study showed that combined omega-3 fatty acid 
and vitamin E supplementation for 2 months in CAD men affected 
serum adiponectin and A-FABP levels, and the adiponectin/A-FABP 
ratio significantly. However, consumption of omega-3 fatty acids 
did not significantly increase adiponectin levels. Omega-3 fatty 
acids with or without vitamin E supplementation had no effects on 
adiponectin gene expression. Adiponectin is mainly secreted by 
adipocytes and certain blood, colon, and small intestine cells (24-
26). Usually, this protein is present in healthy human plasma at 
levels of 3-30 μg/mL (16-18). Adiponectin levels in women are 40% 
higher than those in men. This protein is present in various forms 
in plasma and comprises nearly 0.01% of total plasma proteins (18, 
  OP (n=22) OE (n=20) PP (n=20) P#
Height, cm Before 168.27±1.01 169.98±1.21 167.57±1.56 0.40
Weight, kg Before 79.09±2.08 77.47±2.32 77.28±2.61 0.82
 After 79.24±2.09 77.66±2.30 77.25±2.56 0.80
 Difference 0.145±0.306 0.195±0.324 -0.35±0.248 0.85
 P value§ 0.64 0.55 0.88
BMI, kg/m2 Before 27.97±0.76 26.80±0.72 27.47±0.81 0.55
 After 28.01±0.74 26.85±0.86 27.46±0.79 0.53
 Difference 0.039±0.113 0.053±0.109 -0.014±0.088 0.89
 P value§ 0.73 0.63 0.86
WC, cm Before 97.46±1.96 95.05±1.61 97.35±1.84 0.55
 After 97.95±1.95 94.92±1.45 97.80±1.86 0.41
 Difference 0.318±0.412 -0.125±0.566 0.45±0.380 0.65
 P value§ 0.45 0.82 0.25
HC, cm Before 101.73±1.38 99.65±1.18 99.95±1.22 0.45
 After 101.91±1.284 100.12±1.25 100.30±1.22 0.53
 Difference 0.181±0.408 0.475±0.566 0.350±0.357 0.89
 P value§ 0.66 0.41 0.34
WHR Before 0.95±0.01 0.95±0.01 0.97±0.01 0.43
 After 0.96±0.01 0.95±0.01 0.97±0.01 0.21
 Difference 0.001±0.004 -0.005±0.005 0.001±0.003 0.44
 P value§ 0.78 0.32 0.64
BMI - body mass index; HC - hip circumference; OE - omega-3 fatty acid & vitamin E; OP - omega-3 fatty acid & placebo; PP - placebo & placebo; WHR - waist-to-hip ratio; WC - waist 
circumference; *Mean±SE; #ANOVA; §paired t-test
Table 2. Anthropometric parameters among the groups at baseline and week 8*
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25). Previous studies have shown that adiponectin is a unique anti-
inflammatory and anti-atherogenic adipocytokine. Regulation and 
secretion of this protein are decreased in patients with CAD (14-
16). Plasma adiponectin levels are negatively associated with BMI, 
age, and C-reactive protein (CRP) levels. It has been shown that 
adiponectin increases in people who have lost weight (27). 
However, adiponectin is linked to smoking and gender and the 
levels are lower in males possibly on account of androgenic 
effects (14). The level of this hormone increases with the consump-
tion of Mediterranean foods and increased physical activity. 
Indeed, adiponectin is a protective factor in CVDs and therefore 
assessment of serum adiponectin levels is important. In fact, low 
level of adiponectin is one of the strongest predictors of CAD (27). 
The suggested mechanisms by which adiponectin protectively 
  OP (n=22) OE (n=20) PP (n=20) P#
Energy, Kcal Before 1506.24±125.16 1900.33±161.37 1633.12±142.94 0.14
 After 1647.18±150.41 1890.29±135.31 1522.21±76.53 0.13
 Difference 14.19±15.81 -8.87±18.60 -11.04±14.52 0.54
 P value§ 0.37 0.45 0.96
Carbohydrate, g Before 230.86±18.48 316.36±36.03 264.70±26.17 0.09
 After 260.37±25.69 284.73±20.40 222.50±16.02 0.13
 Difference 29.51±27.90 -31.63±35.41 -42.18±28.25 0.20
 P value§ 0.30 0.15 0.38
Protein, g Before 56.23±5.67 64.84±4.94 67.13±7.93 0.42
 After 54.62±4.56 58.46±4.29 53.01±5.07 0.70
 Difference -1.60±7.62 -6.37±5.29 -14.12±8.63 0.48
 P value§ 0.83 0.11 0.24
Fat, g Before 42.84±6.75 45.96±2.73 37.36±4.33 0.49
 After 46.92±5.57 55.37±5.80 38.08±3.91 0.07
 Difference 4.07±4.82 9.40±6.16 0.714±6.14 0.56
 P value§ 0.40 0.90 0.14
Zinc, mg Before 5.91±0.697 6.12±0.442 5.45±0.568 0.71
 After 5.38±0.560 5.99±0.691 38.08±3.91 0.47
 Difference -0.536±0.971 -0.134±0.708 -0.491±0.689 0.93
 P value§ 0.58 0.85 0.48
Vitamin E, mg Before 3.41±0.809 2.80±0.335 2.64±0.668 0.67
 After 3.59±0.914 3.65±1.03 3.00±0.582 0.84
 Difference 0.18±1.38 0.855±1.09 0.354±0.771 0.90
 P value§ 0.89 0.44 0.65
Selenium, mg Before 0.062±0.008 0.067±0.006 0.068±0.008 0.67
 After 0.055±0.008 0.063±0.010 0.062±0.007 0.84
 Difference -0.007±0.012 -0.004±0.012 -0.005±0.011 0.98
 P value§ 0.54 0.73 0.63
Folate, μg Before 193.69±21.86 252.86±29.78 179.48±24.57 0.11
 After 203.20±22.53 240.37±41.10 159.34±19.11 0.15
 Difference 9.51±33.19 -12.48±52.19 -20.13±30.13 0.85
 P value§ 0.77 0.81 0.51
Vitamin C, mg Before 84.23±1.26 96.92±2.35 93.10±1.57 0.87
 After 111.53±17.78 114.56±21.15 81.25±14.35 0.37
 Difference 27.290±22.46 17.63±21.06 -11.57±12.17 0.34
 P value§ 0.23 0.41 0.35
OE - omega-3 fatty acid & vitamin E; OP - omega-3 fatty acid & placebo; PP - placebo & placebo; *Mean±SE; #ANOVA; §paired t-test
Table 3. Dietary intake among the groups at baseline and week 8*
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affects the process of atherosclerosis include suppression of TNF-
α-induced endothelial adhesion molecule expression, macro-
phage-to-foam cell transformation, and TNF-α expression in mac-
rophages (27).
In the current study, combined omega-3 fatty acid and vitamin 
E supplementation significantly increased adiponectin levels. 
However, consumption of omega-3 fatty acids did not significantly 
increase adiponectin levels. Based on the insignificant changes in 
adiponectin levels in the OP group, it appears that the effect of 
omega-3 fatty acids on serum adiponectin levels cannot be 
ignored. Because other factors, including dose, duration of study, 
and diet, can also induce some effects, diet was assessed in the 
study. However, no significant differences in diet were observed 
between the baseline and end of the study. Stress and inflamma-
tion are other factors that may be involved; however, they were not 
assessed in the current study. Therefore, changes in stress, doses, 
or duration of the study may cause omega-3 fatty acids to induce 
no effects on serum adiponectin levels. A significant difference 
between the OP and OE groups was seen at the end of the study 
compared with the placebo group. However, the variation differ-
ence of this index was statistically significant at the end of the 
study compared with the baseline. According to the findings of the 
current study, it appears that the combination of omega-3 fatty 
acids and vitamin E may result in a marked increase in adiponectin 
levels.
In 2005, an in vitro study of ob/ob mice by Suganami et al. (28) 
showed that EPA may increase adiponectin secretion by reducing 
the secretion of TNFα. No significant increases were seen in the 
mRNA expression of adiponectin in adipose tissues. This indicated 
that EPA could halt NF-κB activity, decrease the mRNA expression 
of TNF-α, and decrease the activation of macrophages, resulting in 
an increase in adiponectin secretion rather than in its mRNA 
expression. In another study in animal models by Mazaki-Tovi et al. 
(29) in 2014, fish oil supplementation significantly increased circu-
  OP (n=22) OE (n=20) PP (n=20) P#
Omega-3 fatty acids, g Before 0.16±0.08 0.12±0.004 0.11±0.06 0.66
 After 0.19±0.01 0.17±0.02 0.14±0.05 0.32
 Difference 0.03±0.04 0.05±0.01 0.03±0.03 0.78
 P value§ 0.25 0.41 0.27
Omega-6 fatty acids, g Before 12.65±1.12 12.02±1.87 11.06±1.63 0.14
 After 14.55±1.41 15.10±1.98 13.08±1.69 0.11
 Difference 1.9±1.58 3.08±1.7 2.02±1.73 0.86
 P value§ 0.28 0.22 0.28
Saturated fatty acids, g Before 10.50±2.43 11.08±0.831 9.37±1.17 0.77
 After 9.88±0.888 9.20±0.857 9.22±1.09 0.84
 Difference -0.702±2.42 -1.88±1.41 -0.149±1.13 0.82
 P value§ 0.77 0.19 0.93
OE - omega-3 fatty acid & vitamin E; OP - omega-3 fatty acid & placebo; PP - placebo & placebo; *Mean±SE; #ANOVA; §paired t-test
Table 4. Fatty acid intake among the groups at baseline and week 8*
  OP (n=22) OE (n=20) PP (n=20) P#
Serum adiponectin, ng/mL Before 6.18±0.396 6.08±0.963 4.66±0.362 0.17
 After 6.50±0.492 8.20±1.09 3.91±0.307 <0.001
 Difference 0.328±0.556 2.12±0.372 -0.845±0.472 <0.001
 P value§ 0.56 <0.001 0.09
Serum FABP4, ng/mL Before 3.20±0.584 2.81±0.443 2.40±0.406 0.51
 After 2.35±0.329 1.80±0.169 2.18±0.274 0.34
 Difference -0.856±0.410 -0.101±0.400 -0.214±0.163 0.25
 P value§ 0.04 0.02 0.69
Adiponectin/FABP4 ratio Before 2.86±0.323 2.88±0.569 3.06±0.380 0.93
 After 2.90±0.394 4.80±0.568 3.28±0.339 0.009
 Difference 0.042±0.294 1.92±0.263 0.225±0.280 <0.001
 P value§ 0.88 <0.001 0.43
OE - omega-3 fatty acid & vitamin E; OP - omega-3 fatty acid & placebo; PP - placebo & placebo; *Mean±SE; #ANOVA; §paired t-test
Table 5. Serum adiponectin levels, serum FABP4 levels, and the adiponectin/FABP4 ratio among the groups at baseline and week 8*
Ramezani et al.
Adiponectin gene in patients with CAD Anatol J Cardiol 2015; 15: 981-9986
lating adiponectin levels in healthy non-obese dogs. In the present 
study, omega-3 fatty acids and a combination of omega-3 fatty 
acids and vitamin E failed to increase the expression of genes in 
PBMCs in male patients with CAD. The adiponectin-induced sup-
pression of monocyte adhesion has been reported to be inhibited 
by a selective AMP-activated protein kinase (AMPK) inhibitor 
compound C in animal models and cell cultures (30). The reduced 
expression and/or function of the adhesion molecules, integrins, 
may underlay the mechanism contributing to reduced monocyte 
adhesion following AMPK activation (31). These findings have sug-
gested that the adiponectin expression of monocytes in PBMCs 
may play an important role in atherogenesis (32). However, studies 
in animal models and cell cultures have shown that overexpres-
sion of adiponectin in macrophages topically produces adiponec-
tin in macrophage cells. This overexpression can also reduce foam 
cell production in arteries and prevent the cells from adhering to 
fibronectin-coated surfaces through the activation of 5-AMPK (32, 
33). These results provide additional evidence that reduced circu-
lating adiponectin levels and decreased adiponectin expression in 
PBMCs may increasingly be involved in atherogenesis (32). 
Neschen et al. (34) showed that consumption of fish oil for 2 weeks 
may increase the expression of adiponectin mRNA in epididymal 
adipose tissue and increase the secretion of this hormone in the 
blood circulation of rats. These data suggest that fish oil is a natu-
rally occurring potent regulator of adiponectin secretion in vivo, 
acting through peroxisome proliferator-activated receptor gamma 
(PPARγ). However, Itoh et al. (15) did not report such an effect in 
their studies. These contradictory results could be due to the dif-
ferences in the amount of drug administered or differences 
between the potential anti-inflammatory effects (34). Another 
study by Deemer et al. (33) showed no effects of omega-3 fatty acid 
supplementation on total serum adiponectin levels in healthy 
women. The current study showed no effects of omega-3 fatty 
acids alone, used for 2 months, on serum adiponectin levels, 
whereas the combination of omega-3 fatty acids and vitamin E 
increased adiponectin levels significantly at the end of the study. 
In general, α- and γ-tocopherols increase the expression of adipo-
nectin and this effect is independent of the vitamin’s antioxidant 
properties. Landrier et al. (35) have shown that tocopherol controls 
adiponectin expression through the regulation of gene expression 
(21).
Induction of PPARγ by vitamin E can increase the available 
PPARγ for binding to PPRE in the promoter region of adiponectin 
(21). Furthermore, PPARγ is required for adiponectin gene tran-
scription and vitamin E plays a role in the PPARγ ligand-dependent 
transcriptional activity, which is associated with PPARγ target 
genes such as adiponectin (21). Iwaki et al. (36) have shown that 
the expression of the adiponectin gene is induced and maintained 
by endogenous or exogenous PPARγ ligands. They identified a 
functional PPRE in the adiponectin promoter, which plays a signifi-
cant role in the transcriptional activation of the adiponectin gene 
in adipocytes by PPARγ. Apparently, combined omega-3 fatty acids 
and vitamin E may have a stronger synergistic effect on adiponec-
tin gene expression. Furthermore, differences in this gene expres-
sion affection in various studies may be linked to differences in the 
administrated doses or duration of intervention. Adiponectin is 
suggested to exist in different forms in the blood circulation, includ-
ing as LMW, MMW, and HMW forms; of these, the predominant 
form is LMW. However, between these 3 forms, HMW adiponectin 
plays an important biological role in relation to metabolic risk fac-
tors and CVDs (14, 16-18). In the present study, total adiponectin 
levels were assessed as well (37). Dodecamer adiponectin can 
bind multiple biotin-conjugated secondary antibodies, leading to 
over calculation. This over calculation could be the cause of low 
levels of LMW adiponectin in patients with high total adiponectin 
levels (>7 μg/mL). Measurement of total adiponectin levels is more 
  OP (n=22) OE (n=20) PP (n=20) P#
ΔCT of adiponectin gene Before 21.02±1.51 18.49±1.03 21.57±0.708 0.28
 After 19.41±0.924 18.13±1.55 20.29±1.23 0.62
 Difference -1.61±1.19 -0.36±2.26 -1.27±1.39 0.91
 P value§ 0.21 0.88 0.37
Changes in the gene expression of adiponectin (ΔΔCT) 10.26±3.91 8.81±6.51 71.91±56.38 0.61
OE - omega-3 fatty acid & vitamin E; OP - omega-3 fatty acid & placebo; PP - placebo & placebo; *Mean±SE; #ANOVA; §paired t-test
Table 6. ΔCT of adiponectin gene and changes in the gene expression of adiponectin among the groups at baseline and week 8*
Physical activity  Low Moderate Severe P§
Before intervention OP 12 (54.5) 8 (36.4) 2 (9.1) 0.27
 OE 16 (51.6) 13 (41.9) 2 (6.5)
 PP 9 (45) 9 (45) 2 (10)
After 2 months of intervention OP 10 (45.5) 9 (40.9) 3 (13.6) 0.41
 OE 12 (60) 7 (35) 1 (5)
 PP 13 (65) 6 (30) 1 (5)
OE - omega-3 fatty acid & vitamin E; OP - omega-3 fatty acid & placebo; PP - placebo & placebo; *Qualitative variables are shown by number (percentage); §chi-square test; ∞Because 
of the low number in the severe group, the moderate and severe groups were merged and the incorporated P value was reported.
Table 7. Comparison of physical activity levels of the participants at baseline and week 8*
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stable when evaluating absolute adiponectin levels, irrespective of 
the multimer size (37).
In this study, omega-3 fatty acids alone or combined with vita-
min E for 2 months were shown to significantly reduce serum 
FABP4 levels in male patients with CAD. Combined intake of 
omega-3 fatty acids and vitamin E further reduced serum FABP4 
levels. However, this difference was not statistically significant. 
FABP, as a new adipocytokine secreted by the adipose tissue, 
plays an important role in the development of metabolic syndrome 
and CVDs (17). Emerging evidence suggests that A-FABP plays an 
important role in metabolism and development of atherosclerosis 
and is positively associated with the severity of coronary artery 
stenosis in patients with CVDs. Furthermore, A-FABP may cause 
increased insulin resistance, hyperglycemia, and lipid abnormali-
ties (17, 22). Recent studies have shown that A-FABP plays an 
essential regulatory role in energy metabolism and inflammation. 
A-FABP may affect atherosclerosis by dysregulation of metabolism 
in the adipose tissue as a result of macrophage activation. A-FABP 
expression in macrophages has been reported to be induced by 
oxidized low-density lipoprotein (LDL). Moreover, A-FABP dysregu-
lates toll-like receptor (TLR) activators (38). In addition, it has been 
reported that an inhibitor of A-FABP markedly reduces atheroscle-
rotic lesions (38). Adiponectin and A-FABP are involved in the 
pathogenesis of atherosclerosis. Adiponectin includes anti-inflam-
matory properties. In contrast, A-FABP is a pro-inflammatory fac-
tor in the development of lipid abnormalities and insulin resistance 
and contributes to the formation of foam cells (22). Studies have 
shown that the adiponectin/A-FABP ratio may be more useful for 
indicating CAD than A-FABP or adiponectin alone. There is a stron-
ger correlation between the Gensini score and adiponectin/A-FABP 
ratio than adiponectin or A-FABP alone in both genders. Previous 
findings indicate that the adiponectin/A-FABP ratio shows meta-
bolic and inflammatory conditions more comprehensively and it is 
less affected by age, sex, BMI, and confounding factors (22).
In the current study, serum A-FABP levels decreased by 2 
months of supplementation with omega-3 fatty acids alone and 
combination of omega-3 fatty acids and vitamin E. It could conse-
quently decrease the progression of cardiovascular complica-
tions. In this study, consumption of omega-3 fatty acids and vitamin 
E increased the adiponectin/A-FABP ratio. At the end of week 8 of 
the study, the adiponectin/A-FABP ratio was significantly different 
between the 3 groups. Furthermore, the difference from the base-
line to the end of the study was statistically significant. However, 
various studies have shown that the genetic involvement in regu-
lating adipocytokine could be associated with atherosclerosis (38). 
The A-FABP allele T87C has been shown to be associated with a 
decreased risk of CVDs (38). However, communication and direct 
interaction of A-FABP polymorphism with atherosclerosis has not 
been fully explained. The effects of A-FABP on lipid and glucose 
metabolisms may be an important mechanism for the progression 
of atherosclerosis (38). In 2011, Doi et al. (38) showed that 
increased plasma A-FABP levels in non-elderly men had a signifi-
cant association with the presence of CAD. However, this associa-
tion was not detected in patients aged ≥65 years old. This shows 
the power of predictive risk factor for CVDs in relation with age. 
Moreover, Doi et al. (38) reported a decrease in the effects of 
A-FABP on the progression of atherosclerosis in older people. 
Therefore, the effects of increased A-FABP levels can be consid-
ered as a risk factor for CVDs in patients under the age of 65 years. 
Furthermore, most studies on CVDs are conducted in men because 
the male gender is a risk factor for CAD (39). Previous studies have 
shown that serum A-FABP levels in female patients with CAD are 
significantly higher than those in male patients with CAD. Usually, 
A-FABP levels in men are lower than those in women. These 
inconsistent differences in serum A-FABP levels in women could 
make it difficult to analyze the survey findings in both genders (39). 
Therefore, only men were included in the current study. It should 
be noted that in the present study, nutrient intake were evaluated 
to show constant levels during the study. In this study, food intake, 
using 24-h food recalls, and physical activity were assessed regu-
larly. At the end of week 8, no significant changes were seen 
compared with the baseline and patients did not change their diet 
and physical activity. In summary, the major highlights of the cur-
rent study include a homogenous population study, assessment of 
total serum adiponectin levels, and study of adiponectin-encoding 
genes using real-time PCR.
Study limitations
The relatively short duration of the study and low doses of omega-
3 fatty acid supplementation are some of the limitations. These fac-
tors may induce a significant influence on adiponectin gene expres-
sion. Therefore, additional large-scale studies with longer duration 
and higher doses are needed to better investigate the subject.
Conclusion
Administration of omega-3 fatty acids with or without vitamin 
E supplementation improves adiponectin levels in patients with 
CAD; however, it results in insignificant changes in adiponectin 
gene expression in PBMCs. This nutritional intervention may pre-
vent complications in such patients occurring on account of 
decreased adiponectin levels.
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